The atopic dermatitis treatment ‘Cibinqo’ may be listed for reimbursement in Korea from July.

According to industry sources, Pfizer Korea completed the pricing negotiations for its new JAK1 inhibitor drug Cibinqo (abrocitinib) with the National Health Insurance Service. Drugs that pass the Health Insurance Policy Deliberative Committee (HIPDC) review can immediately receive reimbursement benefits.

The company had suspended the reimbursement application process after Cibinqo passed the Health Insurance Review and Assessment Service’s Drug Reimbursement Standard Subcommittee review, and resubmitted the application earlier this year after extending the scope of coverage to adults and adol